REPL
NASDAQReplimune Group Inc.
News · 26 weeks55+225%
2025-12-142026-06-07
Mix4290d
- Insider22(52%)
- Other10(24%)
- Analyst8(19%)
- SEC Filings2(5%)
Latest news
25 items- INSIDERChief Commercial Officer Sarchi Christopher sold $110,880 worth of shares (12,000 units at $9.24) as part of a pre-agreed trading plan, decreasing direct ownership by 6% to 180,962 units (SEC Form 4)4 - Replimune Group, Inc. (0001737953) (Issuer)
- PRReplimune Presents Final First-in-Human Data for RP2 in Advanced Solid Tumors During Oral Presentation at the 2026 American Society of Clinical Oncology Annual MeetingWOBURN, Mass., May 31, 2026 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ:REPL), a clinical-stage biotechnology company pioneering the development of novel oncolytic immunotherapies, today presented final first-in-human data for RP2 alone and in combination with nivolumab in patients with advanced solid tumors during an oral session at the 2026 American Society of Clinical Oncology annual meeting. Key findings are detailed below. Oral Presentation: RP2 oncolytic immunotherapy alone and in combination with nivolumab (nivo) in patients with advanced solid tumors: Final safety, efficacy, and biomarker results from the phase 1 first-in-human (FIH) study; Date/Time: May 31, 2026, 9:12 AM
- PRReplimune Presents 3-Year Landmark Overall Survival Analysis from IGNYTE Clinical Trial During Oral Presentation at the 2026 American Society of Clinical Oncology Annual MeetingWOBURN, Mass., May 30, 2026 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ:REPL), a clinical-stage biotechnology company pioneering the development of novel oncolytic immunotherapies, today presented 3-year landmark overall survival data from the IGNYTE clinical trial of RP1 plus nivolumab in patients with anti-PD-1 failed melanoma during an oral session at the 2026 American Society of Clinical Oncology annual meeting. "The overall survival analysis from IGNYTE shows that nearly half of all treated patients in the study were alive at three years, including 83.5% of responders to RP1 plus nivolumab," said Kostas Xynos, MD, PhD, MBA, Chief Medical Officer of Replimune. "This represents a
- ANALYSTReplimune upgraded by Analyst with a new price targetAnalyst upgraded Replimune from Underweight to Neutral and set a new price target of $8.00
- SECReplimune Group Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits8-K - Replimune Group, Inc. (0001737953) (Filer)
- PRReplimune Announces Planned RP1 BLA Resubmission Following Productive Discussion with FDAWOBURN, Mass., May 29, 2026 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ:REPL), a clinical-stage biotechnology company pioneering the development of novel oncolytic immunotherapies, today announced that following collaborative communications with the U.S. Food and Drug Administration (FDA), the Company and the FDA have aligned on a path forward for resubmission and reconsideration of the Biologics License Application (BLA) for RP1 (vusolimogene oderparepvec) in combination with nivolumab for the treatment of advanced melanoma. The company will resubmit the RP1 BLA in the coming days. The FDA has indicated it will treat the BLA resubmission as an urgent matter upon receipt and will pr
- SECSEC Form SCHEDULE 13G filed by Replimune Group Inc.SCHEDULE 13G - Replimune Group, Inc. (0001737953) (Subject)
- INSIDERChief Medical Officer Xynos Konstantinos sold $71,237 worth of shares (14,023 units at $5.08), decreasing direct ownership by 6% to 235,662 units (SEC Form 4) to satisfy tax liability4 - Replimune Group, Inc. (0001737953) (Issuer)
- INSIDERChief Accounting Officer Schwendenman Andrew sold $40,102 worth of shares (7,894 units at $5.08), decreasing direct ownership by 7% to 107,057 units (SEC Form 4) to cover taxes4 - Replimune Group, Inc. (0001737953) (Issuer)
- INSIDERChief Commercial Officer Sarchi Christopher sold $43,820 worth of shares (8,626 units at $5.08), decreasing direct ownership by 4% to 192,962 units (SEC Form 4) (for tax liability)4 - Replimune Group, Inc. (0001737953) (Issuer)
- INSIDERDirector Astley-Sparke Philip sold $89,698 worth of shares (17,657 units at $5.08), decreasing direct ownership by 1% to 1,412,414 units (SEC Form 4) to satisfy withholding tax4 - Replimune Group, Inc. (0001737953) (Issuer)
- INSIDERChief Executive Officer Patel Sushil sold $189,606 worth of shares (37,324 units at $5.08), decreasing direct ownership by 5% to 747,492 units (SEC Form 4) (tax liability)4 - Replimune Group, Inc. (0001737953) (Issuer)
- INSIDERChief Financial Officer Hill Emily Luisa sold $39,685 worth of shares (7,812 units at $5.08), decreasing direct ownership by 3% to 236,556 units (SEC Form 4) (withholding obligation)4 - Replimune Group, Inc. (0001737953) (Issuer)
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Replimune Group Inc.SCHEDULE 13G/A - Replimune Group, Inc. (0001737953) (Subject)
- SECSEC Form SCHEDULE 13G filed by Replimune Group Inc.SCHEDULE 13G - Replimune Group, Inc. (0001737953) (Subject)
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Replimune Group Inc.SCHEDULE 13G/A - Replimune Group, Inc. (0001737953) (Subject)
- PRReplimune to Present at the 2026 American Society of Clinical Oncology (ASCO) Annual MeetingWOBURN, Mass., April 27, 2026 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ:REPL), a clinical stage biotechnology company pioneering the development of novel oncolytic immunotherapies, today announced multiple presentations at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting being held in Chicago from May 29-June 2, 2026. The Company has two abstracts selected for oral presentation, including a 3-year landmark overall survival analysis from the IGNYTE clinical trial of RP1 (vusolimogene oderparepvec) plus nivolumab in anti-PD-1 failed melanoma, and an oral presentation on the final safety, efficacy, and biomarker results from the Phase 1 first-in-human study of RP2
- ANALYSTReplimune downgraded by BMO Capital Markets with a new price targetBMO Capital Markets downgraded Replimune from Market Perform to Underperform and set a new price target of $1.00
- ANALYSTReplimune downgraded by Jefferies with a new price targetJefferies downgraded Replimune from Buy to Hold and set a new price target of $2.00
- ANALYSTReplimune downgraded by AnalystAnalyst downgraded Replimune from Neutral to Underweight
- ANALYSTReplimune downgraded by H.C. WainwrightH.C. Wainwright downgraded Replimune from Buy to Sell
- ANALYSTReplimune downgraded by Leerink Partners with a new price targetLeerink Partners downgraded Replimune from Outperform to Market Perform and set a new price target of $2.00
- ANALYSTReplimune downgraded by Wedbush with a new price targetWedbush downgraded Replimune from Outperform to Neutral and set a new price target of $2.00
- SECReplimune Group Inc. filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits8-K - Replimune Group, Inc. (0001737953) (Filer)
- PRReplimune Receives Complete Response Letter from the FDA for RP1 Biologics License Application for the Treatment of Advanced MelanomaWOBURN, Mass., April 10, 2026 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ:REPL), a clinical stage biotechnology company pioneering the development of novel oncolytic immunotherapies, today announced that the company received a complete response letter (CRL) from the U.S. Food and Drug Administration (FDA) for the Company's Biologics License Application (BLA) for RP1 in combination with nivolumab for the treatment of advanced melanoma. Replimune disagrees with the FDA about whether the data set, upon which breakthrough therapy designation was awarded, is sufficient to allow this promising medicine to be made available to advanced cancer patients. In the IGNYTE trial, patients with co
REPL FAQ
7 questionsWhat does Replimune Group Inc. do?
Replimune Group, Inc., a biotechnology company, develops oncolytic immuno-gene therapies to treat cancer. It uses its proprietary Immulytic platform to design and develop product candidates that are intended to activate the immune system against cancer. The company's lead product candidate is RP1, a selectively replicating version of herpes simplex virus 1, which is in Phase I/II clinical trials for a range of solid tumors; and that is in Phase II clinical trials for patients with cutaneous squamous cell carcinoma. It is also developing RP2, which is in Phase I clinical trials for an...Where does REPL stock trade?
Replimune Group Inc. (REPL) is listed on NASDAQ.What sector and industry is REPL in?
Replimune Group Inc. operates in the Health Care sector, Biotechnology: Biological Products (No Diagnostic Substances) industry.When did Replimune Group Inc. go public?
Replimune Group Inc. (REPL) completed its IPO in 2018.What are analysts saying about REPL?
Replimune Group Inc. has had 8 recent analyst actions on file. The most recent action was from Analyst: Neutral with a $800.00 price target on 2026-05-29.What companies are similar to REPL?
Notable peers in the same industry include AMGN (Amgen Inc.), GILD (Gilead Sciences Inc.), ARGX (argenx SE), RVMD (Revolution Medicines Inc.), BIIB (Biogen Inc.). Compare REPL side-by-side with any of them on Quantisnow.How can I track REPL on Quantisnow?
Quantisnow aggregates Replimune Group Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow REPL to receive live email and push alerts on every new disclosure.